Stoke Therapeutics, Inc. financial data

Symbol
STOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
45 Wiggins Avenue, Bedford, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ASOthera Pharmaceuticals, Inc. (to 11/24/2014)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 687 % -23.9%
Debt-to-equity 37.1 % +5.34%
Return On Equity -57.9 % -9.35%
Return On Assets -42.2 % -7.84%
Operating Margin -756 % +40.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.6M shares +19%
Common Stock, Shares, Outstanding 52.3M shares +18.3%
Entity Public Float 290M USD -2.36%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 55.8M shares +26.2%
Weighted Average Number of Shares Outstanding, Diluted 55.8M shares +26.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 15.2M USD +71.4%
Research and Development Expense 85.6M USD +5.16%
General and Administrative Expense 44.1M USD +11%
Operating Income (Loss) -115M USD -2.01%
Nonoperating Income (Expense) 11M USD +50%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -104M USD +1.33%
Earnings Per Share, Basic -2.19 USD/shares +13.4%
Earnings Per Share, Diluted -2.19 USD/shares +13.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 193M USD +0.74%
Other Assets, Current 4.29M USD +15.9%
Assets, Current 297M USD +20.6%
Property, Plant and Equipment, Net 4.77M USD -26.3%
Operating Lease, Right-of-Use Asset 5.5M USD +50.8%
Assets 308M USD +19.8%
Accounts Payable, Current 3.95M USD +154%
Liabilities, Current 44.5M USD +104%
Operating Lease, Liability, Noncurrent 3.55M USD +143%
Other Liabilities, Noncurrent 3.61M USD +121%
Liabilities 65M USD -2.51%
Accumulated Other Comprehensive Income (Loss), Net of Tax -15K USD +96%
Retained Earnings (Accumulated Deficit) -454M USD -29.6%
Stockholders' Equity Attributable to Parent 243M USD +27.6%
Liabilities and Equity 308M USD +19.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.6M USD -15%
Net Cash Provided by (Used in) Financing Activities 1.72M USD -96.2%
Net Cash Provided by (Used in) Investing Activities 9.99M USD -81.2%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 52.3M shares +18.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.9M USD -117%
Deferred Tax Assets, Valuation Allowance 133M USD +36.1%
Deferred Tax Assets, Gross 133M USD +36.1%
Operating Lease, Liability 5.83M USD +49%
Depreciation 563K USD -5.7%
Payments to Acquire Property, Plant, and Equipment 12K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -103M USD +0.83%
Lessee, Operating Lease, Liability, to be Paid 6.53M USD +61.3%
Property, Plant and Equipment, Gross 12.5M USD +14.8%
Operating Lease, Liability, Current 2.28M USD -7.06%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.66M USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.31M USD +2.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +106%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 704K USD +414%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.56M USD +1391%
Deferred Tax Assets, Operating Loss Carryforwards 52.6M USD -8.84%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 697M USD +28.8%
Share-based Payment Arrangement, Expense 25.4M USD +4.45%